沙利度胺联合常规化疗方案治疗急性白血病的临床疗效及对患者免疫水平的影响

Clinical Efficacy of Thalidomide Combined with Routine Chemotherapy in the Treatment of Acute Leukemia and the Influence on the Immune Level of Patients

目的探讨沙利度胺联合常规化疗方案治疗急性白血病的临床疗效及对患者免疫水平的影响。方法将60例急性白血病患者随机分为研究组(n=30,沙利度胺^(+)常规化疗)和常规组(n=30,常规化疗),比较两组的疾病缓解率、免疫水平及不良反应情况。结果研究组疾病缓解率为93.33%,高于常规组的70.00%(P<0.05)。治疗后,两组的CD_(3)^(+)、CD_(4)^(+)、CD_(4)^(+)/CD_(8)^(+)、NK细胞水平均升高,CD_(4)^(+)CD_(25)^(+)均降低,且研究组的CD_(3)^(+)、CD_(4)^(+)、CD_(4)^(+)/CD_(8)^(+)、NK细胞水平高于常规组,CD_(4)^(+)CD_(25)^(+)水平低于常规组(P<0.05)。两组的不良反应发生率(16.67%vs.20.00%)比较无统计学差异(P>0.05)。结论沙利度胺联合常规化疗方案治疗急性白血病患者可明显提高疾病缓解率,改善患者免疫功能,且不会增加不良反应,值得临床推广应用。

Objective To explore the clinical efficacy of thalidomide combined with routine chemotherapy in the treatment of acute leukemia and the influence on the immune level of patients.Methods 60 patients with acute leukemia were randomly divided into study group(n=30,thalidomide+routine chemotherapy)and routine group(n=30,routine chemotherapy).The disease remission rate,immune level and adverse reactions of the two groups were compared.Results The disease remission rate of the study group was 93.33%,higher than 70.00% of the routine group(P<0.05).After treatment,the levels of CD_(3)^(+),CD_(4)^(+),CD_(4)^(+)/CD_(8)^(+) and NK cells in the two groups increased,and the levels of CD_(4)^(+)CD_(25)^(+) decreased(P<0.05);The levels of CD_(3)^(+),CD_(4)^(+),CD_(4)^(+)/CD_(8)^(+) and NK cells in the study group were higher than those in the routine group,and the CD_(4)^(+)CD_(25)^(+)level was lower than that in the routine group(P<0.05).No statistical difference was found in the incidence of adverse reactions(16.67%vs.20.00%)between the two groups(P>0.05).Conclusions Thalidomide combined with routine chemotherapy in the treatment of patients with acute leukemia can significantly improve the disease remission rate,improve the immune function of patients,without increasing the adverse reactions,which is worthy of clinical promotion and application.